| abstract |
A pharmaceutical composition for use as dopamin-D3-receptor antagonists or agonists comprising thiadiazole compounds of the formula I, where A is a straight-chain or branched C3-C14-alkylene group which may comprise at least one group selected from S, a double bond, B is a radical of the formula, R1 is H, NR2R3, or C1-C6-alkyl; R2 is H or C1-C6-alkyl; R3 has the meanings indicated for R2; X is N; Ar is phenyl, pyridyl or pyrimidyl, where Ar may have from one, two or three substituents which are selected, independently of one another, from OR3, C1-C6-alkyl, halogen, CN, NO2, CF3, CHF2, phenyl, SR2, Cyclohexyl, Pyrrolyl, Pyrrolidinyl and where Ar may also be fused to a carbocyclic ring to form a naphthyl group, and the salts thereof with physiologically tolerated acids. The compounds according to the invention have a high affinity for the dopamine D3 receptor and can therefore be used to treat disorders of the central nervous system. |